Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.61 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538720 | 0.86 | SMN1; SMN2 (0.68) | SRD5A2PLA2G4BSMN1; SMN2MAPK1PLA2G4A | |
| SCHEMBL4509911 | 0.81 | KMT2A (0.57) | PLA2G4BSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL6539987 | 0.80 | SRD5A2 (0.91) | SRD5A2PLA2G4BMAPK1PLA2G4APKM | |
| SCHEMBL16438642 | 0.79 | MAPK1 (0.62) | SMN1; SMN2RAB9ANPC1MAPK1HIF1A | |
| SCHEMBL9328026 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1MAPK1HIF1A | |
| SCHEMBL16438577 | 0.78 | POLB (0.59) | SMN1; SMN2RAB9ANPC1MAPK1HIF1A | |
| SCHEMBL16438484 | 0.78 | CYP1A2 (0.62) | SMN1; SMN2RAB9ANPC1MAPK1HIF1A | |
| SCHEMBL13639141 | 0.77 | TP53 (0.57) | PLA2G4BMAPK1PLA2G4APKMTP53 | |
| SCHEMBL12302172 | 0.77 | PLA2G4B (0.66) | SRD5A2PLA2G4BMAPK1PLA2G4APKM | |
| SCHEMBL8070858 | 0.76 | SRD5A2 (1.00) | SRD5A2PLA2G4BRAB9ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | SRD5A2 2616/4885PLA2G4B 757/4885SMN1; SMN2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.